ArticleOphthalmology science2026
Symmetry in the Enlargement Rates of Large Hypertransmission Defects between Eyes in Age-Related Macular Degeneration.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Symmetry in the Enlargement Rates of Large Hypertransmission Defects between Eyes in Age-Related Macular Degeneration.Ophthalmology science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Purpose: The symmetry of macular atrophy growth rates between eyes of patients with bilateral nonexudative age-related macular degeneration (AMD) was assessed to determine if both eyes could be used in clinical trials to test therapies that might slow the growth of atrophy. Design: Retrospective review of prospectively collected swept-source OCT angiography images. Subjects: Patients with bilateral nonexudative AMD with ≥1 large hypertransmission defect (hyperTD) in both eyes were included. Methods: All large hyperTDs, defined by a greatest linear dimension ≥250 μm, were identified by 2 independent graders and annotated using a semiautomated algorithm. Growth rates were assessed using the area, square root (sqrt) area, and the perimeter-adjusted growth-rate strategies. Baseline lesion sizes were stratified using a size breakpoint of 0.9 disc area (DA). Intereye comparisons of annual hyperTD growth rates were performed. Power analyses were calculated to determine the sample sizes needed for different clinical trial designs. Main Outcome Measures: Intereye concordance of growth rates was evaluated using Lin concordance correlation coefficients, and inter eye growth-rate agreement was evaluated using Bland-Altman analyses. Sample sizes for a 2-arm clinical trial design were calculated to detect a 30% reduction in growth rates in the treatment arm with 80% power and a 2-sided α = 0.05. Results: Sixty-four subjects (128 eyes) were followed for a mean of 4.2 ± 1.9 years, providing 942 annualized growth-rate intervals. Prior to stratification by baseline size of 0.9 DA, intereye concordance was high (r Conclusions: High intereye concordance in hyperTD growth rates was observed for lesions ≥0.9 DA using 3 different growth-rate strategies. Regardless of the growth-rate strategy used, recruitment of fellow eyes in a paired-eye study for localized treatments or both eyes for systemic treatments resulted in a marked reduction in sample sizes, with improved clinical trial efficiency. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.